Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 13, Cantor Fitzgerald reiterated its “Overweight” rating and $13.00 price target for Taysha.

An MRI scan of a patient with a brain disorder, depicting the company’s successful treatments for central nervous system disorders.

According to their research note, three key factors played a key role in the analysts’ decision. First, Cantor Fitzgerald’s representatives met with Taysha’s management team at the International Rett Syndrome Foundation (IRSF) Scientific Meeting. The occasion provided an opportunity for the analysts to fine-tune their outlook for the company.

Secondly, the affirmation was based on recent positive Phase 1/2 clinical data and a regulatory update for TSHA-102. TSHA-102 is an adeno-associated virus (AAV)-based gene therapy in development for Rett syndrome. The data presented at the IRSF meeting was a reprise presentation of previously released results.

Third, Cantor Fitzgerald noted strong positive sentiment among stakeholders. The sentiment analyzed includes that of investors and key opinion leaders regarding Taysha’s developments. However, the analysts were quick to acknowledge that the sentiment was not reflected in the stock’s current market valuation.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company. It develops AAV-based gene therapies for rare monogenic diseases of the central nervous system. Its lead programs include TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, among others, targeting conditions such as CLN1, CLN7, and Angelman syndrome.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper.

Disclosure: None.